>

Teva Pharmaceutical Profile

<div class='circular--portrait' style='background:#FF9E01;color: white;font-size:3em;padding-top: 40px;;'>TEV</div>

Performance

7 / 100

Odds of Distress

Equity ratings for Teva Pharmaceutical Industries are calculated based on Macroaxis scoring framework. The performance scores are derived for the period starting November 21, 2019 and ending today February 19, 2020. Click here to learn more.

Teva Pharmaceutical Profile

The stock is undergoing above average trading activities. Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. Teva Pharmaceutical Industries Limited was founded in 1901 and is headquartered in Petach Tikva, Israel. Teva Pharmaceutical is traded on BATS Exchange in USA. more on Teva Pharmaceutical
Legal NameTeva Pharmaceutical Industries
CEOCarlo NotaristefaniView All
Thematic Classification
Currently Active Investing Idea
  Israel Wall Street
View All
Average Analyst Recommendation
Current trade recommendation based on an ongoing consensus estimate among financial analysis covering Teva Pharmaceutical
Macroaxis Advice
Macroaxis buy hold or sell recommendation provided in the context of your current investment horizon and risk tolerance.
Horizon: 30 days (very short)Advice
Bond Rating
Teva Pharmaceutical Industries (TEVA) is traded on BATS Exchange in USA and employs 42,535 people. The company currently falls under 'Large-Cap' category with current market capitalization of 14.25 B. Teva Pharmaceutical conducts business under Healthcare sector and is part of Drug Manufacturers?Specialty & Generic industry. The entity has 1.09 B outstanding shares of which 57.09 M shares are at this time shorted by private and institutional investors with about 3.04 trading days to cover. TEVA PHARM INDS A currently holds about 1.98 B in cash with 748 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.81.
Check Teva Pharmaceutical Probability Of Bankruptcy

Ownership Allocation (%)

Teva Pharmaceutical Target Price Odds Analysis

Odds Below 12.22HorizonTargetOdds Above 12.22
97.79%30 days 12.22 2.19%
Based on normal probability distribution, the odds of Teva Pharmaceutical to move above current price in 30 days from now is roughly 2.19 (This Teva Pharmaceutical Industries probability density function shows the probability of Teva Pharmaceutical Stock to fall within a particular range of prices over 30 days) .

Teva Pharmaceutical Top Holders

Teva Pharmaceutical Major Institutional Holders

InstituionSecurity TypeTotal SharesValue
Lmr Partners LlpDebt24.2 M2.3 B
Wellington Management Group LlpCommon Shares77.7 M761.4 M
Berkshire Hathaway IncCommon Shares43.2 M423.8 M
Susquehanna International Group LlpPut Options10.7 M104.8 M
Susquehanna International Group LlpCall Options7.7 M75 M
View Teva Pharmaceutical Diagnostics

Teva Pharmaceutical Risk Profiles

Teva Pharmaceutical Against Markets

Did you try this?

Run Crypto Correlations Now

   

Crypto Correlations

Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
All  Next Launch Module

Teva Pharmaceutical Upcoming and Recent Events

Teva Pharmaceutical Company Earnings Announcements Dates

Upcoming Quarterly Earning ReportMay 8, 2017
Next Earnings ReportAugust 3, 2017
Next Fiscal Quarter EndMarch 31, 2017
Next Fiscal Year EndFebruary 12, 2018
Last Quarter Report DateDecember 31, 2016
Last Earning Anouncement DateMarch 31, 2016

Teva Pharmaceutical Corporate Directors

Nechemia Peres Independent Director
Moshe Many Independent Director
Roger Abravanel Independent Director
Additionally take a look at World Market Map. Please also try Correlation Analysis module to reduce portfolio risk simply by holding instruments which are not perfectly correlated.
Company logos by clearbit